Turning Point Therapeutics, Inc.

NasdaqGS:TPTX 주식 보고서

시가총액: US$3.8b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Turning Point Therapeutics 미래 성장

Future 기준 확인 2/6

Turning Point Therapeutics은 연간 수입과 매출이 각각 24.7%와 73.9% 증가할 것으로 예상되고 EPS는 연간 27.8%만큼 증가할 것으로 예상됩니다.

주요 정보

24.7%

수익 성장률

27.8%

EPS 성장률

Biotechs 수익 성장24.1%
매출 성장률73.9%
향후 자기자본 수익률n/a
애널리스트 커버리지

Good

마지막 업데이트n/a

최근 미래 성장 업데이트

Recent updates

Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report

Jul 21

We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Mar 23
We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

Dec 06
Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

The Take On Turning Point Therapeutics

Dec 03

Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Aug 15
Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

Aug 04
Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer

Jun 17

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 08
Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

Feb 26
Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study

Jan 29

Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher

Jan 22
Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher

We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn

Jan 13
We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn

Turning Point Therapeutics: An Emerging Growth Story In TKI-Resistant Cancers

Dec 28

Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?

Dec 15
Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?

Turning Point Therapeutics' lead candidate nabs accelerated review for lung cancer

Dec 08

Turning Point Therapeutics EPS beats by $0.12, beats on revenue

Nov 12

수익 및 매출 성장 예측

NasdaqGS:TPTX - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2024178-368-304-3587
12/31/202340-449-307-3409
12/31/202211-392-271-2937
6/30/20221-342-263-259N/A
3/31/20226-275-199-197N/A
12/31/202131-237-156-154N/A
9/30/202131-205-136-133N/A
6/30/202155-157-91-90N/A
3/31/202150-132-72-71N/A
12/31/202025-157-84-83N/A
9/30/202025-131-65-63N/A
6/30/2020N/A-134-84-82N/A
3/31/2020N/A-119-78-75N/A
12/31/2019N/A-72-59-58N/A
9/30/2019N/A-60-53-52N/A
6/30/2019N/A-46-40-40N/A
3/31/2019N/A-34-29-28N/A
12/31/2018N/A-25-24-24N/A

애널리스트 미래 성장 예측

수입 대 저축률: TPTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: TPTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: TPTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: TPTX 의 수익(연간 73.9% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: TPTX 의 수익(연간 73.9% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: TPTX 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견